Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps

• DOI: 10.1002/lary.27852
• Publication Date: 2019-02-05T14:05:28Z
• Authors: Neil Bhattacharyya; Sara Villeneuve; Vijay N. Joish; Caroline Amand; Leda Mannent; Nikhil Amin; Paul Rowe; Jaman Maroni; Laurent Eckert; Tony Yang; Asif Khan
• Keywords: Adult; Male; cost of illness; chronic rhinosinusitis with nasal polyposis; 03 medical and health sciences; Nasal Polyps; 0302 clinical medicine; Cost of Illness; Medicine and Health Sciences; MANAGEMENT; Humans; Allergy/Rhinology; Sinusitis; healthcare resource utilization; Retrospective Studies; Rhinitis; Disease burden; ADULTS; Health Care Costs; Middle Aged; Patient Acceptance of Health Care; United States; PREVALENCE; 3. Good health; Case-Control Studies; Chronic Disease; economic burden; ASTHMA; Female; HEALTH-CARE UTILIZATION; ENDOSCOPIC SINUS SURGERY

Objectives/HypothesisEstablish treatment patterns and economic burden in US patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) versus without chronic rhinosinusitis (CRS). Determine comparative costs of subgroups with high clinical burden.Study DesignObservational, retrospective, case‐control study.MethodsThis study matched patients with CRSwNP to patients without CRS (1:1) using the Truven Health MarketScan US claims database. Categorical and continuous variables were compared using McNemar test and paired t test (normal distribution) or Wilcoxon signed rank tests (non‐normal distribution). Within subgroups, χ2 and Wilcoxon or t tests were used (normal distribution).ResultsThere were 10,841 patients with CRSwNP and 10,841 patients without CRS included. Mean age in the CRSwNP cohort was 45.8 years; 56.2% were male. During follow‐up, patients with CRSwNP had an increased diagnosis of asthma versus patients without CRS (20.8% vs. 8.1%, respectively; P < .001). Annual incremental costs were $11,507 higher for patients with CRSwNP versus those without CRS. Costs were higher in subgroups of patients with CRSwNP undergoing functional endoscopy sinus surgery (FESS), with a comorbid diagnosis of asthma, receiving oral corticosteroids, or macrolides versus the overall CRSwNP group. Patients with CRSwNP undergoing FESS had the highest costs of the four subgroups ($26,724, $22,456, $20,695, and $20,990, respectively).ConclusionsAnnual incremental costs were higher among patients with CRSwNP versus without CRS. Patients with CRSwNP with high clinical burden had higher overall costs than CRSwNP patients without.Level of EvidenceNALaryngoscope, 129:1969–1975, 2019